All In Biotech

Drug Trial Radar · NCT06881823

Study to Assess [177Lu]Lu-PSMA-R2 (AAA602) and [225Ac]Ac-PSMA-R2 (AAA802) in Participants With PSMA-positive HRLPC

NeoPSMA: A Phase I/II, Open-label, Multi-center Study of Neoadjuvant Treatment With [177Lu]Lu-PSMA-R2 (AAA602) and [225Ac]Ac-PSMA-R2 (AAA802) in Adults With Prostate-specific Membrane Antigen (PSMA) Positive High-risk Localized Prostate Cancer (HRLPC) Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection

Last checked: Nov 20, 2026Latest source record: Dec 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Withdrawn

Status

Withdrawn

Enrollment

0

Actual

Start

Jun 29, 2026

Primary completion

Mar 31, 2030

Study completion Jun 1, 2033

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Mar 18, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this trial is to learn more about the effects of AAA602 and AAA802 in men with prostate-specific membrane antigen (PSMA) positive high-risk localized prostate cancer (HRLPC) before surgery to remove the prostate and lymph nodes present in the pelvis area. Lymph nodes are small structures near the prostate that help fight infections. These lymph nodes are removed during surgery because they are a site the disease can spread to.

Conditions

  • Prostate Cancer

Interventions

  • AAA602Drug

    \[177\]Lu-PSMA-R2 Radiopharmaceutical solution for injection/infusion.

  • AAA802Drug

    \[225\]Actinium-PSMA-R2 radiopharmaceutical solution for injection/infusion

  • Gallium (68Ga) gozetotideDrug

    Radioligand Imaging compound. Provided as a kit for radiopharmaceutical preparation of gallium (68Ga) gozetotide. Solution for injection.

  • Piflufolastat (18F)Drug

    Radioligand Imaging compound. Provided as a ready-to-use radiopharmaceutical.

  • Flotufolastat F 18Drug

    Radioligand Imaging compound. Provided as a ready to use radiopharamceutical.

  • 18F-PSMA-1007Drug

    Radioligand Imaging compound. Provided as a ready to use radiopharmaceutical.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with dose-limiting toxicities (DLTs) (Phase l)Time frame: At the end of cycle 1 (each cycle is maximum 6 weeks)
  2. Biochemical recurrence free survival (BFS) (Phase ll)Time frame: From the date of surgery until the date of confirmed biochemical recurrence or death due to any cause, whichever occurs first assessed to approximately 60 months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.